Skip to main content

Table 2 Clinical baseline characteristics of GBM patient samples (n = 46)

From: System-based approaches as prognostic tools for glioblastoma

 Newly-diagnosed (n = 31, 67%)Recurrent (n = 15, 33%)
Age (median, range) [years]57 (16–75)53 (12–74)
Sex
 M14 (45%)10 (67%)
 F17 (55%)5 (33%)
Location
 Left side10 (32%)3 (20%)
 Right side18 (58%)10 (67%)
 Other2 (6%)2 (13%)
 Not available1 (3%) 
MGMT promoter methylation
 Methylated11 (35%)6 (40%)
 Unmethylated14 (45%)8 (53%)
 Not available6 (19%)1 (7%)
Treatment
 None31 (100%)6 (40%)
 TMZ + radiotherapy 7 (47%)
 TMZ + radiotherapy + Avastin + Irinotecan 1 (7%)
 TMZ + radiotherapy + Cilengitide 1 (7%)
PFS (median, 95%CI) [months]11.1 (8.4–16.8)5.8 (2.3–7.6)
  1. Abbreviations: TMZ Temozolomide, MGMT O6-methylguanine-DNA methyltransferase